SREBF2 and hepatocellular carcinoma: Furthermore, SREBP2’s interaction with HBx suggests that pharmacologically targeting this pathway may be particularly effective in patients where HBx plays a significant role in promoting viral replication and pathogenesis, such as in those with high viral loads or those at risk for hepatocellular carcinoma (HCC).